PCI Biotech - Fundamentale forhold (PCIB)

TekBot · september 8, 2022, 9:04am

PCI Biotech: Mandatory notification regarding trade of shares

Rodjer · september 8, 2022, 9:09am

Tar jo helt av

TekBot · september 8, 2022, 9:58am

Correction: PCI Biotech: Mandatory notification regarding trade of shares

TheLion · september 8, 2022, 10:13am

Ja, men helt rå fantastisk 16000 NOK på high risk. Kanskje det var aksje drivende joker RS snakket om eller ikke.

Buffet · september 8, 2022, 7:27pm

Hun har vell fått 200 000 kr hvert år siden 2019 bare for å være styremedlem. Så spenstig å plutselig bare legge 8000 kr på bordet og dobble aksjebeholdningen! Det gjør man ikke uten å ha ståltro!

Tekspert · oktober 1, 2022, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@lenny (390 likes)

@polygon (138 likes)

@Bompiole (128 likes)

PCI Biotech - Småprat (PCIB)

Ja da har vi fønne oss ett nytt bunn nivå enn så lenge på 2.60-70,en forferdelig utvikling, i mine auge er kommande Q Pcib siste sjanse til å vise at det er liv laga for dei.Håper dei forstår dei må på en alvorlig frierferd til markedet og nåværende aksjonærer vi må få vite ALT som ikkje er såkalla børssensitiv informasjon.Håper også Ånden som går dukker opp og redegjør om søken eller ikke på ny Ceo,hvilke forsøk ble gjort for å prøve finansiere Vacc studiet,er Vacc studiet avlyst for godt?eller berre lagt på is?Er interessen for Nac god som fungerende Ceo fortalte meg over telefonen?desverre har vi ikkje Sørlendingen på Q til stille spørsmål så eg oppfordre alle aksjonærer og dei som er interessert i Pcib om å sende inn spørsmål.På tide vi stakkars aksjonærer i dette skakkjørte selskapet får litt respekt og openhet fra dets styre og stell

Resten av topp 10:

@Roc (101 likes)
@abacus (93 likes)
@arve19541 (74 likes)
@StockDZ (71 likes)
@Logdec (67 likes)
@nordpolen (55 likes)
@HiroProtagonist (50 likes)

Gratulerer!

Kaizers · oktober 3, 2022, 1:47pm

Er det noe håp i PCIB? Verdt å satse noe på aksjen?
Noen triggere fremover eller er kun utvanning og evt. ikke videre studier i vente?

Tekspert · november 1, 2022, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@lenny (247 likes)

@polygon (134 likes)

@Roc (101 likes)

Resten av topp 10:

@Bompiole (99 likes)
@StockDZ (78 likes)
@arve19541 (59 likes)
@abacus (57 likes)
@Oxion (55 likes)
@nordpolen (55 likes)
@HiroProtagonist (50 likes)

Gratulerer!

TekBot · november 17, 2022, 4:44pm

PCI Biotech: Invitation to Q3 2022 results presentation

Oslo, Norway, 17 November 2022 - PCI Biotech (OSE: PCIB) invites to an online
presentation of the company’s Q3 2022 interim report on Wednesday 23 November
2022, 08:30am - 09:30am CET (local time).
…

Vis børsmeldingen

The presentation will be held as a live webcast and can be accessed through
www.pcibiotech.com. There will be a Q&A session at the end of the presentation
and it will be possible to post written questions through the webcast console or
through a teleconference facilitated for attendees intending to ask questions
verbally during the Q&A session.

The company will be represented by Ronny Skuggedal (CEO/CFO), Anders Høgset
(CSO), and Morten Luhr (BD Manager) and the presentation will be held in
Norwegian.

PCI Biotech’s Q3 2022 interim report will be released on 23 November 2022 at
07.00am CET. The interim report and presentation will be made available on
www.newsweb.no and on the company’s webpage, www.pcibiotech.com.

For further information, please contact:
Ronny Skuggedal, CEO / CFO
Email: rs@pcibiotech.no
Mobile: +47 9400 5757

About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and
commercialisation of novel therapies through its innovative photochemical
internalisation (PCI) technology platform. PCI induces triggered endosomal
release that is used to unlock the true potential of therapeutic modalities.

The fimaVacc programme aims to enhance immunotherapy in cancer, by triggered
endosomal release of antigens or nucleic acids encoding antigens, or
immunostimulatory factors. In the fimaNAc programme endosomal release is
utilised to provide intracellular delivery of nucleic acids, such as mRNA and
RNAi therapeutics, thereby addressing one of the major bottlenecks facing this
emerging and promising field.

For further information, please visit: www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379
Oslo

Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

Kilde

Kreft · november 17, 2022, 5:42pm

Jeg tror fortsatt på Pcib. Det er noe her, i denne teknologien.

TekBot · november 23, 2022, 6:01am

PCI Biotech interim Q3 2022 report

Oslo (Norway), 23 November 2022 - PCI Biotech (OSE: PCIB), today announces its
interim Q3 2022 results. Please find enclosed the report and presentation.

…

Vis børsmeldingen

Highlights

Corporate
*Efforts to finance a Ph II clinical trial in head and neck cancer did not,
under the current market conditions, result in a feasible way forward and the
company reported in August that it will not conduct a company-sponsored Ph II
trial with the fimaVacc technology. This entailed a downsizing of the clinical
team, which is enacted during the second half of 2022, with full cost reduction
effect in Q1 2023. The cash position of NOK 67 million per end of Q3 enables an
estimated financial runway into 2024

*The company now focus its efforts and resources on non-clinical research,
exploring new fields of use for the PCI technology platform utilising fimaNAc
for dermatology and bioprocessing applications, and fimaVacc for intratumoural
immunotherapy

fimaNAc - dermatology and bioprocessing
*The first step for the dermatology discovery project is to demonstrate fimaNAc-
mediated nucleic acid delivery in a wound model. External feasibility
experiments are contracted, with expected readout 1H 2023

*The bioprocessing discovery project exploring applications specifically suited
to the strengths of the PCI technology has matured and is now focused on in-
house experiments of fimaNAc for use in viral manufacturing

fimaVacc - intratumoural immunotherapy
*Exploring approaches aiming to identify novel immunotherapy treatment
combinations with promising efficacy

fimaChem
*All major study closure activities are expected to be completed before the end
of the year. The remaining cash effect for the closure process is estimated up
to NOK -3 million from 1st October 2022

Collaborations
*In August 2022, a preclinical collaboration was initiated with Mymetics, aiming
to explore technological synergies for possible enhancement of cancer therapy

*The collaboration with Mendus has been reviewed for progress and value and was
closed in November 2022

Corporate - other
*Ronny Skuggedal was appointed Interim CEO effective 1st June and promoted to
CEO effective 1st September 2022. Amir Snapir, CMO, left the company in
September 2022

Ronny Skuggedal, CEO of PCI Biotech, comments: “The company has during the
restructuring process managed to maintain momentum and focus. The next step for
fimaNAc in dermatological applications is taken to demonstrate fimaNAc-mediated
delivery of a model mRNA in an ex vivo human skin wound model, acting as a
stepping-stone to partnership-driven development. The bioprocessing project has
advanced by further assessments to narrow down the most promising areas for
fimaNAc and to secure IP. There is a significant need for improvements within
bioprocessing and we believe that our technology has potential to address
challenges within viral manufacturing”

A live webcast in Norwegian will be held today, Wednesday 23 November 2022, at
08:30am - 09:30am CET (local time).

The presentation can be followed as a live webcast, accessed through the link
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20221123_1 or the
company’s website under “Investors - Reports and presentations - Webcasts”.

Q&A session
There will be a Q&A session at the end of the webcast and it will be possible to
post written questions through the webcast console or through a teleconference,
mainly facilitated for attendees intending to ask questions verbally during the
Q&A session.

Dial-in details for the teleconference, mainly facilitated for verbal questions
during Q&A session:
If you plan to use this facility, please join the event 5-10 minutes prior to
the scheduled start time using the dial-in numbers below. A line mediator will
provide information on how to ask questions.
Norway +47 2195 6342 / Sweden +46 40682 0620 / Denmark +45 7876 8490 / United
Kingdom +44 203 7696 819 / United States +1 646 787 0157. If your country is not
listed, we recommend that you use the dial-in details for UK.

When prompted, provide the confirmation code or event title.

Confirmation Code: 436187
Event title: PCI Biotech Holding Quarterly Report - Q3

The interim report and the presentation will also be available on www.newsweb.no
and on the company’s webpage, www.pcibiotech.com from 07:00am (CET) on 23
November 2022.

For further information, please contact:
Ronny Skuggedal, CEO / CFO
Email: rs@pcibiotech.no
Mobile: +47 9400 5757

About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and
commercialisation of novel therapies through its innovative photochemical
internalisation (PCI) technology platform. PCI induces triggered endosomal
release that is used to unlock the true potential of therapeutic modalities.

The fimaVacc programme aims to enhance immunotherapy in cancer, by triggered
endosomal release of antigens or nucleic acids encoding antigens, or
immunostimulatory factors. Enhancement of relevant immune responses with
protein- and peptide-based vaccines were successfully demonstrated in humans
through an extensive Phase I study in healthy subjects. In the fimaNAc programme
endosomal release is utilised to provide intracellular delivery of nucleic
acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major
bottlenecks facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com
(http://www.pcibiotech.com)
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379
Oslo

Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

Kilde

TekBot · november 23, 2022, 3:15pm

Financial calendar

TekBot · november 25, 2022, 5:09pm

PCI Biotech: Employee share option scheme

Oslo, 25 November 2022 - PCI Biotech (OSE: PCIB), today announce that the Board
of Directors has granted share options to key employees.

…

Vis børsmeldingen

In accordance with the authorisation granted by the Annual General Meeting 25
May 2022 and the remuneration policy adopted by the Annual General Meeting 28
May 2021, the Board of Directors of PCI Biotech Holding ASA (“PCI Biotech”) has
awarded a total of 570,000 share options to key employees. Each share option
gives the right to subscribe for or acquire one share per option (after PCI
Biotech’s choice), at a strike price of NOK 1.90, equal to the volume weighted
average share price (VWAP) for the last 5 days of trade prior to the grant date.
However, the current nominal value of the share is NOK 3.00 and the strike price
cannot be lower than the nominal value of the share at the future exercise
date(s). The share options are granted without consideration and are subject to
service based vesting conditions, and the share options will vest equally over a
three-year vesting term. The share options are lapsing in Q3 2027. Further
details about the share option program are described in PCI Biotech’s
remuneration policy.

According to the remuneration policy the BoD will at allotment of share options
seek to allot a number of share options with a total fair value, calculated
according to the Black-Scholes model, that is partly linked to the annual base
salary for each individual. Other elements that will be assessed in the
allotment are the balance between total short- and longterm performance based
rewards, current value of share options held, overall performance, work
responsibility, importance of retention and position.

The number of share options granted is based on these guidelines and in
addition, the share options are granted with a value cap of 20 times the strike
price of NOK 1.90. If this value cap threshold is met all share options will
vest immediately and be available for exercise.

To ensure long-term ownership by executive management, shares obtained by
exercise of share options shall be held for at least one year, except shares to
be sold immediately to cover transaction costs and tax under a so-called cash
less exercise. Through the long-term incentive program the board expects members
of the executive team to build up and maintain share ownership with a market
value equal to at least one-year gross base salary, before any shares may be
sold. No lock-up elements are applicable for other employees.

Of the 570,000 share options, 360,000 share options were allotted to the
following primary insiders:

220,000 share options were allotted to Ronny Skuggedal, CEO. After the
allotment, Ronny Skuggedal holds a total portfolio of 360,000 unexercised share
options and 55,000 shares.

120,000 share options were allotted to Anders Høgset, CSO. After the allotment,
Anders Høgset holds a total portfolio of 250,000 unexercised share options and
64,800 shares.

20,000 share options were allotted to Kristin Eivindvik, CDO. After the
allotment, Kristin Eivindvik holds a total portfolio of 110,000 unexercised
share options and 25,200 shares.

Primary insider notifications pursuant to the market abuse regulation article
19 are attached.

The current authorisation, as of 25 May 2022, allows for a total of 2,790,000
share options, of which 1,000,000 now have been granted by the Board of
Directors.

For more information, please contact:
Ronny Skuggedal, CEO, rs(a)pcibiotech.no, Mobile: +47 9400 5757

This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and to section 5-12 of the Norwegian
Securities Trading Act.

Kilde

Tekspert · desember 1, 2022, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@Oxion (51 likes)

@lenny (38 likes)

@StockDZ (34 likes)

Resten av topp 10:

@polygon (32 likes)
@olafalo (30 likes)
@Bompiole (23 likes)
@TyrionIV (20 likes)
@FiloD (19 likes)
@alfred_e_neuman (17 likes)
@nordpolen (15 likes)

Gratulerer!

Tekspert · januar 1, 2023, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@Oxion (54 likes)

@Bompiole (39 likes)

@polygon (31 likes)

Resten av topp 10:

@FiloD (30 likes)
@StockDZ (30 likes)
@olafalo (20 likes)
@TyrionIV (20 likes)
@Handyman (15 likes)
@abacus (15 likes)
@Ruben2 (14 likes)

Gratulerer!

TekBot · januar 20, 2023, 9:15am

Flagging

TekBot · januar 20, 2023, 11:37am

Flaggemelding relatert til PCIB

Tekspert · februar 1, 2023, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@Oxion (88 likes)

@polygon (77 likes)

[quote=“polygon, post:5276, topic:30365”]

@fleksnes (73 likes)

Resten av topp 10:

@Bompiole (58 likes)
@Snoeffelen (55 likes)
@StockDZ (42 likes)
@Tjommien (41 likes)
@olafalo (40 likes)
@h3nk1 (37 likes)
@FiloD (33 likes)

Gratulerer!

TekBot · februar 13, 2023, 2:36pm

PCI Biotech: Invitation to Q4 2022 results presentation

Oslo, Norway, 13 February 2023 - PCI Biotech (OSE: PCIB) invites to an online
presentation of the company’s Q4 2022 interim report on Friday 17 February
2023, 08:30am - 09:30am CET (local time).
…

Vis børsmeldingen

The presentation will be held as a live webcast and can be accessed through
www.pcibiotech.com. There will be a Q&A session at the end of the presentation
and it will be possible to post written questions through the webcast console or
through a teleconference facilitated for attendees intending to ask questions
verbally during the Q&A session.

The company will be represented by Ronny Skuggedal (CEO/CFO), Anders Høgset
(CSO), and Morten Luhr (BD Manager), and the presentation will be held in
Norwegian.

The interim report and presentation will be made available on www.newsweb.no and
on the company’s webpage, www.pcibiotech.com, from 07.00am CET the same day.

For further information, please contact:
Ronny Skuggedal, CEO / CFO
Email: rs@pcibiotech.no
Mobile: +47 9400 5757

About PCI Biotech
PCI Biotech is a biopharmaceutical company focussing on development and
commercialisation of novel therapies through its innovative photochemical
internalisation (PCI) technology platform. PCI induces triggered endosomal
release that is used to unlock the true potential of therapeutic modalities.

The fimaNAc programme utilises the proven capability of the PCI technology for
intracellular delivery of nucleic acids. The technology can be used for most
types of nucleic acids, ranging from oligonucleotides through mRNA and plasmids
to viral vectors. The development of the fimaNAc programme is currently focussed
on selected applications within dermatology and bioprocessing, well suited to
the specific strengths of the PCI technology. The fimaVACC programme aims to
enhance immunotherapy in cancer, by triggered endosomal release of antigens or
nucleic acids encoding antigens, or immunostimulatory factors. For further
information, please visit: www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379
Oslo

Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

Kilde

TekBot · februar 17, 2023, 6:02am

PCI Biotech interim Q4 2022 results

Oslo (Norway), 17 February 2023 - PCI Biotech (OSE: PCIB), today announces its
interim Q4 2022 results. Please find enclosed the report and presentation.

…

Vis børsmeldingen

Highlights

fimaNAc - dermatology and bioprocessing
*The first phase of the dermatology program, to demonstrate topical fimaNAc-
mediated nucleic acid delivery in a preclinical wound model, is on track for
readout 1H 2023. Positive results will be utilised for seeking co-development
with partners having nucleic acid-based drug candidates

*The bioprocessing program has matured, and the first patent application has
been filed on use of fimaNAc in viral vector manufacturing. Further studies are
planned for 1H 2023 to strengthen fimaNAc’s value proposition and intellectual
property

fimaVacc - intratumoural immunotherapy
*PCI Biotech is exploring approaches aimed at identifying novel immunotherapy
treatment combination, and first patent application for an undisclosed treatment
approach is underway for filing in Q1 2023

Corporate
*The cash position of NOK 57 million per year-end enables an extended estimated
financial runway towards the end of 2024 with current plans

*All major study closure activities for the RELEASE trial are completed and the
estimated remaining cash effect for the closure process is less than NOK -1
million. Downsizing of the full clinical team, reported in August, was enacted
during second half of 2022 with full cost reduction effect in Q1 2023

*The company focusses its efforts and resources on pre-clinical research in
areas where there is need for novel drug delivery systems, with a partnership-
driven development strategy. fimaNAc is focussed on dermatology and
bioprocessing applications, and fimaVacc on intratumoural immunotherapy

Ronny Skuggedal, CEO of PCI Biotech, comments: “The first phase of the fimaNAc
dermatology program to demonstrate topical delivery of a model mRNA in a human
skin wound model has been initiated, with the intention to act as a stepping-
stone to partnership-driven development. The bioprocessing program has made good
progress, and we have started to seek external feedback on our approach. The
restructuring process is close to be completed, and with increased visibility
our financial runway is extended towards the end of 2024 with current plans.”

PCI Biotech will for future quarterly reports disclose more condensed interim
financial information, tailored to its operations and effective from Q1 2023.

A live webcast in Norwegian will be held today, Friday 17 February 2023, at
08:30am - 09:30am CET (local time).

The presentation can be followed as a live webcast, accessed through the link
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20230217_2 or the
company’s website under “Investors - Reports and presentations - Webcasts”.

Q&A session
There will be a Q&A session at the end of the webcast and it will be possible to
post written questions through the webcast console or through a teleconference,
mainly facilitated for attendees intending to ask questions verbally during the
Q&A session.

Dial-in details for the teleconference, mainly facilitated for verbal questions
during Q&A session:
If you plan to use this facility, please join the event 5-10 minutes prior to
the scheduled start time using the dial-in numbers below. A line mediator will
provide information on how to ask questions.
Norway +47 2195 6342 / Sweden +46 40682 0620 / Denmark +45 7876 8490 / United
Kingdom +44 203 7696 819 / United States +1 646 787 0157. If your country is not
listed, we recommend that you use the dial-in details for UK.

When prompted, provide the confirmation code or event title.

Confirmation Code: 436187
Event title: PCI Biotech Q4 2022

The interim report and the presentation will also be available on www.newsweb.no
and on the company’s webpage, www.pcibiotech.com from 07:00am (CET) today.

For further information, please contact:
Ronny Skuggedal, CEO / CFO
Email: rs@pcibiotech.no
Mobile: +47 9400 5757

About PCI Biotech
PCI Biotech is a biopharmaceutical company focussing on development and
commercialisation of novel therapies through its innovative photochemical
internalisation (PCI) technology platform. PCI induces triggered endosomal
release that is used to unlock the true potential of therapeutic modalities.

The fimaNAc programme utilises the proven capability of the PCI technology for
intracellular delivery of nucleic acids. The technology can be used for most
types of nucleic acids, ranging from oligonucleotides through mRNA and plasmids
to viral vectors. The development of the fimaNAc programme is currently focussed
on selected applications within dermatology and bioprocessing, well suited to
the specific strengths of the PCI technology. The fimaVacc programme aims to
enhance immunotherapy in cancer, by triggered endosomal release of antigens or
nucleic acids encoding antigens, or immunostimulatory factors. For further
information, please visit: www.pcibiotech.co

Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379
Oslo

Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act

Kilde